Normophthal is a Russian capsule supplement containing a tiny two-amino-acid peptide, promoted to support the retina (the eye's light-sensing layer) and healthy aging. One small study linked adding it to standard care with better retinal function in early-stage retinal degeneration. Longer-life claims rest on animal and cell studies. The main practical risk is letting it replace proven glaucoma or macular degeneration treatment. Nearly all evidence comes from its developers. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Best-corrected visual acuity | 20/20 (logMAR 0.0) or better | Central vision |
| Visual field mean deviation | 0 to −2 dB; track change from own baseline | Peripheral vision loss |
| Intraocular pressure | 10–18 mmHg | Glaucoma risk |
| OCT nerve fiber layer and macular thickness | No established target; track change from own baseline | Structural retinal loss |
| Full-field electroretinogram (a- and b-wave) | a-wave 30–60 μV; b-wave 225–400 μV | The only functional endpoint in the Normophthal trial |
| Fasting glucose | 75–90 mg/dL | Glucose-lowering interaction |
| HbA1c | 4.8–5.4% without diabetes; individual target on insulin | Hypoglycemia risk and glucose trend |
| INR (warfarin users only) | Individual therapeutic target, commonly 2.0–3.0 | Bleeding interaction |
Cadence: Complete eye examination before a first course; acuity and symptoms at the end of each 1-month course; full eye testing every 6–12 months (every 3–6 months with glaucoma or macular degeneration) on the same devices; glucose checks most frequent during the first 2–4 weeks of each course; INR rechecked 1–2 weeks after starting.